ZJ23F1201946Determine the necessary mass, volume, or concentration for preparing a solution.
Vunakizumab (anti-IL-17a) (Ab175703) - ELISA
Immobilized hu-IL-17A at 1.0 μg/mL can bind Vunakizumab (anti-IL-17a) (Ab175703) with the EC₅₀ of 48.60 ng/mL.
Vunakizumab (anti-IL-17a) - Primary antibody, specific to IL17A, >95%, Human IgG1, INHIBITOR of Interleukin 17A inhibitor, INHIBITOR of Interleukin 17A inhibitor
Disponible para pedir
GRADE & PURITY Animal Free ? Animal-free — produced without animal-derived components to reduce contamination risk. Use in biomanufacturing and culture avoiding animal-origin material. Carrier Free ? Carrier-free — supplied without added carrier protein/stabilizer. Use when carriers (e.g. BSA) would interfere with conjugation or sensitive assays. Recombinant ? Recombinant — produced via recombinant expression for defined sequence and consistency. Use for reproducible, animal-free proteins of known origin. Validated ? Validated grade — performance confirmed in defined applications before release. Use when you want documented assurance the reagent works as stated. ExactAb™ ? ExactAb™ — Aladdin's antibody line emphasizing precision and validated quality. Use for reliable, specificity-validated antibody applications. Low Endotoxin ? Low-endotoxin grade — endotoxin reduced to low controlled levels. Use in sensitive biological work where high endotoxin would interfere. Azide Free ? Azide-free — without sodium azide preservative. Use in conjugations, cell work, or assays where azide is toxic or inhibitory. ≥95%(SDS-PAGE&SEC-HPLC) See COA
Application
Animal Model, ELISA, Flow Cytometry, Functional Assay
Host species
Human
Reactive species
Cynomolgus monkey, Human, Mouse, Rat
Isotype
Human IgG1
Conjugation
Unconjugated